Graig Suvannavejh
Stock Analyst at Mizuho
(2.15)
# 1,474
Out of 4,479 analysts
130
Total ratings
41.76%
Success rate
-7.68%
Average return
Main Sectors:
Top Industries:
33 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ITCI Intra-Cellular Therapies | Maintains: Buy | $96 → $100 | $68.54 | +45.90% | 9 | Jun 21, 2024 | |
| AXSM Axsome Therapeutics | Reiterates: Buy | n/a | $78.93 | - | 16 | Jun 12, 2024 | |
| INSM Insmed | Maintains: Buy | $36 → $82 | $64.50 | +27.13% | 3 | Jun 7, 2024 | |
| ADAP Adaptimmune Therapeutics | Maintains: Buy | $9 → $3 | $1.05 | +185.71% | 1 | May 17, 2024 | |
| IMTX Immatics | Maintains: Buy | $14 → $16 | $12.02 | +33.11% | 3 | May 16, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Neutral | $4 → $3 | $1.74 | +72.41% | 5 | May 14, 2024 | |
| IMCR Immunocore Holdings | Maintains: Buy | $90 → $88 | $34.80 | +152.87% | 6 | May 13, 2024 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Buy | $39 → $30 | $8.01 | +274.53% | 4 | May 7, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $60 → $52 | $34.98 | +48.66% | 4 | Apr 29, 2024 | |
| ADVM Adverum Biotechnologies | Maintains: Buy | $40 → $22 | $6.84 | +221.64% | 4 | Apr 29, 2024 | |
| IMRX Immuneering | Maintains: Buy | $20 → $8 | $1.09 | +633.94% | 1 | Apr 2, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Neutral | $3.5 | $1.78 | +96.63% | 1 | Mar 27, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $42 → $40 | $30.00 | +33.33% | 14 | Feb 27, 2024 | |
| CERE Cerevel Therapeutics Holdings | Maintains: Neutral | $25 → $45 | $41.23 | +9.14% | 9 | Feb 16, 2024 | |
| HALO Halozyme Therapeutics | Maintains: Neutral | $45 → $40 | $51.30 | -22.03% | 4 | Jan 18, 2024 | |
| TERN Terns Pharmaceuticals | Maintains: Buy | $17 → $10 | $6.72 | +48.81% | 5 | Nov 27, 2023 | |
| ALEC Alector | Maintains: Buy | $10 → $9 | $4.34 | +107.37% | 4 | Nov 17, 2023 | |
| BTAI BioXcel Therapeutics | Reiterates: Neutral | $4 | $1.12 | +257.14% | 8 | Aug 23, 2023 | |
| ATHA Athira Pharma | Maintains: Buy | $6 → $5 | $2.52 | +98.41% | 2 | May 15, 2023 | |
| VIGL Vigil Neuroscience | Initiates: Buy | $15 | $4.01 | +274.53% | 1 | Mar 31, 2023 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $31 → $35 | $42.34 | -17.34% | 5 | Nov 10, 2022 | |
| KOD Kodiak Sciences | Maintains: Neutral | $9 → $8 | $2.24 | +257.14% | 6 | Nov 10, 2022 | |
| CYTK Cytokinetics | Maintains: Buy | $71 → $57 | $54.84 | +3.94% | 2 | May 24, 2022 | |
| TGTX TG Therapeutics | Maintains: Sell | $8 → $5 | $18.31 | -72.69% | 3 | Apr 19, 2022 | |
| VALN Valneva SE | Initiates: Buy | n/a | $7.28 | - | 1 | Jun 1, 2021 | |
| DSGN Design Therapeutics | Initiates: Neutral | n/a | $3.20 | - | 1 | Apr 20, 2021 | |
| EWTX Edgewise Therapeutics | Initiates: Neutral | n/a | $18.38 | - | 1 | Apr 19, 2021 | |
| VOR Vor Biopharma | Initiates: Sell | n/a | $0.91 | - | 1 | Mar 2, 2021 | |
| IPHA Innate Pharma | Initiates: Neutral | n/a | $2.06 | - | 1 | Nov 24, 2020 | |
| ARQT Arcutis Biotherapeutics | Upgrades: Buy | n/a | $9.30 | - | 2 | Nov 9, 2020 | |
| GLPG Galapagos NV | Downgrades: Sell | n/a | $25.34 | - | 1 | Oct 21, 2020 | |
| PRLD Prelude Therapeutics | Initiates: Neutral | n/a | $3.73 | - | 1 | Oct 20, 2020 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Sell | n/a | $105.09 | - | 1 | Sep 14, 2020 |
Intra-Cellular Therapies
Jun 21, 2024
Maintains: Buy
Price Target: $96 → $100
Current: $68.54
Upside: +45.90%
Axsome Therapeutics
Jun 12, 2024
Reiterates: Buy
Price Target: n/a
Current: $78.93
Upside: -
Insmed
Jun 7, 2024
Maintains: Buy
Price Target: $36 → $82
Current: $64.50
Upside: +27.13%
Adaptimmune Therapeutics
May 17, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $1.05
Upside: +185.71%
Immatics
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $12.02
Upside: +33.11%
Amylyx Pharmaceuticals
May 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $1.74
Upside: +72.41%
Immunocore Holdings
May 13, 2024
Maintains: Buy
Price Target: $90 → $88
Current: $34.80
Upside: +152.87%
EyePoint Pharmaceuticals
May 7, 2024
Maintains: Buy
Price Target: $39 → $30
Current: $8.01
Upside: +274.53%
Apellis Pharmaceuticals
Apr 29, 2024
Maintains: Neutral
Price Target: $60 → $52
Current: $34.98
Upside: +48.66%
Adverum Biotechnologies
Apr 29, 2024
Maintains: Buy
Price Target: $40 → $22
Current: $6.84
Upside: +221.64%
Immuneering
Apr 2, 2024
Maintains: Buy
Price Target: $20 → $8
Current: $1.09
Upside: +633.94%
Corvus Pharmaceuticals
Mar 27, 2024
Maintains: Neutral
Price Target: $3.5
Current: $1.78
Upside: +96.63%
Harmony Biosciences Holdings
Feb 27, 2024
Maintains: Buy
Price Target: $42 → $40
Current: $30.00
Upside: +33.33%
Cerevel Therapeutics Holdings
Feb 16, 2024
Maintains: Neutral
Price Target: $25 → $45
Current: $41.23
Upside: +9.14%
Halozyme Therapeutics
Jan 18, 2024
Maintains: Neutral
Price Target: $45 → $40
Current: $51.30
Upside: -22.03%
Terns Pharmaceuticals
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $6.72
Upside: +48.81%
Alector
Nov 17, 2023
Maintains: Buy
Price Target: $10 → $9
Current: $4.34
Upside: +107.37%
BioXcel Therapeutics
Aug 23, 2023
Reiterates: Neutral
Price Target: $4
Current: $1.12
Upside: +257.14%
Athira Pharma
May 15, 2023
Maintains: Buy
Price Target: $6 → $5
Current: $2.52
Upside: +98.41%
Vigil Neuroscience
Mar 31, 2023
Initiates: Buy
Price Target: $15
Current: $4.01
Upside: +274.53%
Rhythm Pharmaceuticals
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $42.34
Upside: -17.34%
Kodiak Sciences
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $2.24
Upside: +257.14%
Cytokinetics
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $54.84
Upside: +3.94%
TG Therapeutics
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $18.31
Upside: -72.69%
Valneva SE
Jun 1, 2021
Initiates: Buy
Price Target: n/a
Current: $7.28
Upside: -
Design Therapeutics
Apr 20, 2021
Initiates: Neutral
Price Target: n/a
Current: $3.20
Upside: -
Edgewise Therapeutics
Apr 19, 2021
Initiates: Neutral
Price Target: n/a
Current: $18.38
Upside: -
Vor Biopharma
Mar 2, 2021
Initiates: Sell
Price Target: n/a
Current: $0.91
Upside: -
Innate Pharma
Nov 24, 2020
Initiates: Neutral
Price Target: n/a
Current: $2.06
Upside: -
Arcutis Biotherapeutics
Nov 9, 2020
Upgrades: Buy
Price Target: n/a
Current: $9.30
Upside: -
Galapagos NV
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $25.34
Upside: -
Prelude Therapeutics
Oct 20, 2020
Initiates: Neutral
Price Target: n/a
Current: $3.73
Upside: -
Jazz Pharmaceuticals
Sep 14, 2020
Downgrades: Sell
Price Target: n/a
Current: $105.09
Upside: -